Growing Measles Threat Spurs NanoViricides to Test Antiviral Solution

NanoViricides has announced the evaluation of its antiviral drug NV-387 for measles treatment. As cases rise, with CDC reporting 712 confirmed and three deaths, the need for a medical response grows urgent. Measles virus is linked to RSV, against which NV-387 has shown efficacy by mimicking HSPG to combat viral spread.

NanoViricides encourages the use of NV-387 under FDA guidelines for "Emergency Expanded Access for an Individual Patient." Previous Phase I trials highlighted its safety, showing effectiveness against various viruses using HSPG for infection.

Despite vaccination efforts, with a requirement for 95-97% coverage for herd immunity, cases continue, partly due to a potentially waning vaccine. Without a drug, containment may remain elusive, prompting calls for supported development of NV-387 as a viable solution.